| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.1 |
| Profit before tax | -20.8 | -12.2 |
| Net income | -20.8 | -12.2 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: OVID. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Ovid Therapeutics Inc.: key numbers
- Share price
- $2.40Close, Nov 16
- Market cap
- $453M
- Shares outstanding
- 188.73MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Ovid Therapeutics Inc.
All →Ovid Therapeutics Financial Results
Ovid Therapeutics reported third quarter 2026 financial results, ending the period with $161.4 million in cash and marketable securities. The company highlighted clinical progress for OV329 in focal epilepsy and the initiation of a Phase 1 study for OV4071, with a projected financial runway extending into 2029.
- Term
- Q3 2026
“The third quarter was focused on execution toward multiple, near-term clinical milestones across our pipeline. We anticipate findings from two high potential programs in early 2027, which may respectively demonstrate the broad potential of KCC2 direct activation and the anticonvulsant profile of OV329, a next-generation GABA-AT inhibitor.”
Meg Alexander, President and Chief Executive Officer